#1Bahi Smartphone Biometric Health Assessment Scott Montgomery Chief Executive Officer JANUARY 2024 Vlado Bosanac Founder/Head of Strategy#2Confidential - Do not duplicate or distribute without the written permission of Advanced Health Intelligence Ltd This presentation ("Presentation") has been prepared by Advanced Health Intelligence Ltd ("Advanced Health Intelligence" or "Company"). You must read and accept the conditions in this notice before considering the information set out in or referred to in this Presentation. If you do not agree, accept or understand the terms on which this Presentation is supplied, or if you are subject to the laws of any jurisdiction in which it would be unlawful to receive this Presentation or which requires compliance with obligations that have not been complied with in respect of it, you must immediately return or destroy this Presentation and any other confidential information supplied to you by Advanced Health Intelligence. By accepting this document, you acknowledge and agree to the conditions in this notice and agree that you irrevocably release Advanced Health Intelligence from any claims you may have (presently or in the future) in connection with the provision or content of this Presentation. NO OFFER This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction (and will not be lodged with the ASIC). This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire shares of Advanced Health Intelligence and does not and will not form any part of any contract for the acquisition of shares of Advanced Health Intelligence. SUMMARY INFORMATION This Presentation contains summary information about Advanced Health Intelligence, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Advanced Health Intelligence or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act. While Advanced Health Intelligence has taken every effort to ensure the accuracy of the material in the presentation, neither the Company nor its advisers have verified the accuracy or completeness of the information, or any statements and opinion contained in this Presentation. NOT INVESTMENT ADVICE Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Advanced Health Intelligence and the impact that different future outcomes may have on Advanced Health Intelligence. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. Advanced Health Intelligence is not licensed to provide financial product advice in respect of Advanced Health Intelligence shares. Cooling off rights do not apply to the acquisition of Advanced Health Intelligence shares. INVESTMENT RISK An investment in Advanced Health Intelligence shares is subject to known and unknown risks, some of which are beyond the control of Advanced Health Intelligence. Advanced Health Intelligence does not guarantee any particular rate of return or the performance of Advanced Health Intelligence nor does it guarantee any particular tax treatment. An investment in Advanced Health Intelligence should be considered as Highly Speculative and High Risk due to the start up nature of the Company and its proposed business. FINANCIAL DATA All dollar values in this Presentation are in Australian dollars (A$ or AUD) unless otherwise stated. FORWARD-LOOKING STATEMENTS This Presentation may contain forward looking statements. The words 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'could', 'may', 'target', 'plan' and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. You should not place undue reliance on forward-looking statements and neither Advanced Health Intelligence nor any of its directors, employees, advisers or agents assume any obligation to update such information. DISCLAIMER None of Advanced Health Intelligence's respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, employees and agents, have authorized, permitted or caused the issue, submission, dispatch or provision of this Presentation and, except to the extent referred to in this Presentation, none of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by any of them. To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of your participation in an investment in Advanced Health Intelligence and the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Advanced Health Intelligence and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation. Statements made in this Presentation are made only as the date of this Presentation. The information in this Presentation remains subject to change without notice.#3Biometric health screening using just a smartphone no health professional or additional equipment required, not even a wearable. Mission Vision Provide health monitoring access to every smartphone user globally. Ubiquitous health monitoring Investor Presentation - January 2024 3#4Executive summary Advanced Health Intelligence (ASX-NASDAQ:AHI) Is a global digital health solution Corporate overview AHI sells its dHaaS (digital health-as-a-service) technology to healthcare, insurance and government customer segments around the world in a business- to-business model (B-to-B). AHI completed two acquisitions in 2022, expanding its capabilities to offer mass population health monitoring using only a user's smartphone. AHI holds patents in Australia, USA, Japan, Korea, Singapore, New Zealand, China and Canada and expects to add to the patent portfolio. AHI screens for health risk stratification using only a smartphone by capturing biometric data, including vital signs, body composition, dimension, and indicative blood markers. In addition, AHI offers DermaScan which covers 588 skin conditions across 133 categories. AHI enables its partners to estimate 41 biometrics across 5 health categories in order to triage their users into directionalized care. Issuer Exchange Shares on issue As at 19 Jan 2024 NASDAQ ADR ADR Ratio 28:1, As at 19th Jan 2024 Employee headcount Current partners addressable audience Intellectual property X ASX Nasdaq Advanced Health Intelligence Ltd. Australian Securities Exchange (ASX), Nasdaq Capital Market (NASDAQ) 241,428,086 including ADR cover 1,940,773 34 across Australia, Singapore, USA, Canada, South Africa, Netherlands > 250 million addressable users across AHI's current partners 24 patents, across Australia, USA, Japan, Korea, Singapore, New Zealand, China And Canada Investor Presentation - January 2024 4#5Recent announcements 120 days of momentum 5 January 2024: Bearn Signs 3 New Partners Further Boosting AHI Shared Reven 28 December 2023: AHI Secures $2.27 million in R & D Tax Incentive Scheme 6 December 2023: AHI Completes Formal Agreements with Pharmak Direct 30 November 2023: AHI to Launch Medically Approved Mobile Phone-Based AF Asses 3 November 2023: AHI Signs Binding Term Sheet with Vietnam Based OneClinic 21 September 2023: AHI Signs LOI to Develop & Deploy a Digital Underwriting Solution 12 September 2023: AHI Signs Collaboration Agreement with Abu Dhabi based Bin Farhood Group newsfile Advanced Health Intelligence Ltd. םםם Recent News Advanced Health Intelligence Obtains Overseas R&D Reimbursement Under Australia's Research and Development Tax Incentive Scheme (R&DTI) f South Perth, Australia-Newsle Corp-August 17, 2023)- Advanced Health intelligence Ltd (ASX AND NASDAQ AH About - Services- Newsroom- Login Q Search Blog Contact Aahi Sign up for Alerts Sign up to receive news releases by email for Advanced Health Intelligence Ltd or all Technology, Healthcare and Hospitals, of approved expenditures incurred abroad for overseas Research & Development (R&D) of intellectual property (P) under Stock Quote Advanced Health Intelligence Ltd Signs Collaboration Agreement with IntelliGen FZ-LLC Highlights An enters a second commercial agreement in the UAE intelligen Founders have worked with, and within the Government, Healthcare needs across the Middle East Intellien will receive up to 2,000,000 A shares for the delivery of USD$30,000,000 License to A within the region. IntelliGen to receive a revenue share on all sales across the region Advanced Health Intelligence to re-enter China with Exclusive License Deal with Changlin Network Technology Ltd Highlight execute a binding exclusive, perpetual license with Shanghai-based Changlin Network Technology LM Changin is backed by founders with 50 years of global health insurance sector experience. The license agreement in ONE SCOR PHARMAK DIRECT CLINIC quotemedia RSS Feeds Our last 10 news releases for Advanced available for public consumption Full text RSS feeds which can be categorized by type *Unisure health life global BEARN earn while you burn! Investor Presentation - January 2024 LO 5#6The realities of the rising costs in healthcare Global healthcare expenditure will reach 10% of GDP by 2040 The rising costs of healthcare have become a global challenge and a major reality for both developed and developing countries. According to the World Health Organization (WHO), the global healthcare. expenditure is projected to reach 10% of the Gross Domestic Product (GDP) by the year 20404. By streamlining health assessment and triage into a smartphone experience, AHI offers pathways into improving population health literacy and empowering individuals to take better control of their health. 6.64b There are 6.64b smartphone users in the world today - 83.32% of the world's population¹. 17.9m Cardiovascular disease accounts for most noncommunicable disease deaths - 17.9m annually². 1 in 4 Nearly half of adults in the U.S. (47%) have hypertension yet only 1 in 4 have it under control³. Investor Presentation - January 2024 Sources 1.How many smartphones are in the world?, https://bankmycell.com/ 2.Noncommunicable diseases, https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases/ 3. Facts about Hypertension in the United States, https://cdc.gov 4.Global spending on health: Weathering the storm https://www.who.int/publications/i/item/9789240017788#7Trends in digital health Healthcare is increasingly powered by Al " Major tech vendors continuously compete to upgrade their Al platforms with regular enhancements, as projections show the global healthcare Al market will reach nearly 188 billion U.S. dollars by 20301 Med-PaLM 2 reached 86.5% accuracy on the MedQA medical exam benchmark in research in line with a medical expert. The PALM 2 general pass mark is -60%2 by Google FDA " Forbes FDA Clearance Granted for First Al-Powered Medical Device to Detect All Three Common Skin Cancers (Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma)³ Investor Presentation - January 2024 Sources 1. https://www.forbes.com/sites/davidchou/2023/12/17/google-launches-a-healthcare-focused-llm/?sh=4c37ca7d729c 2. https://sites.research.google/med-palm/ 3. https://www.dermasensor.com/fda-clearance-granted-for-first-ai-powered-medical-device-to-detect-all-three-common-skin-cancers-melanoma- basal-cell-carcinoma-and-squamous-cell-carcinoma/ 8 00#8Trends in digital health More prevalence means more access 62% of smartphone users use their phone for mHealth. A more common smartphone activity than online banking (57%), job searches (42%) 1.2. < 6% of the world's adults use a wearable². 90% of the world's adults use a smartphone². 10:09 THUMIDITY 54% 65 FT/9 12:16 975 3.8* 1K reviews myAir™ for Air10™ by ResMed ResMed 100K+ Downloads E Everyone Install About this app Track your sleep therapy progress and access helpful tips and videos. Medical Sources: ¹https://www.sciencedirect.com/science/article/abs/pii/S1934148217303829 Investor Presentation - January 2024 0 < 2https://mobius.md/2021/10/25/11-mobile-healthstatistics/#:~:text=Most%20smartphone%20users%20have%20used, 5. 2https://www.statista.com/forecasts/1143723/smartphone-users-in-the-world # 417 9#9Realising digital transformation in healthcare Biometric health assessment for global populations 02 03 Our aim is to revolutionize healthcare with our proprietary technology. This scalable technology allows the convenient and cost-effective distribution of health assessments to derive real-time risk stratification and automate digital triage at population-scale with improved accuracy. Our comprehensive suite of digital health solutions creates a cohesive ecosystem that supports healthcare success, addressing the Triple Aim. 01 Population health assessments and engagement Provide scalable access and automation through smartphones to easily assess health vital signs without need for more devices or health professionals. Targeted digital interventions Personalized eHealth programs for targeted outcomes (i.e. the opposite of one-size-fits-all public health). Telehealth or physician consultation for condition management Where clinically appropriate, referrals into partner- selected telehealth and physician clinics. $ Very low cost per person Varies by provider $ $ SUB-CLINICAL Investor Presentation - January 2024 Very low cost per person Entire population People identified as high risk of selected illness Continuum of care People diagnosed with selected illnesses 10 CLINCAL#10Our solutions Proactive risk management in the palm of your hand All on the smartphone in less than 15 minutes - no additional wearables or hardware needed. Remote and contactless biometric-derived health assessment for risk estimates associated with blood pressure, heart rate, HbA1c, cholesterol, (LDL and HDL), triglycerides and many more. Wide range of predicted health risks including obesity, heart attack risk, stroke risk, 10-year Framingham cardiovascular disease risk, diabetes and more. Seamless triage capability - lower risk individuals can be referred into subclinical care options while moderate to higher risk can be referred into telehealth or higher care options. Investor Presentation - January 2024 Biometric Health Assessment A ahi About You 63 weight Heigh 22 Male Cardiorespiratory Health Resting Heart Rate Cardiorespiratory Fitness gen a Your Cantory essent a good 10-Year Cards Based on resting heart and deng studies ouh 7% chance of dig Shore in the next 10 years Cardiacar De E 2 v Z R 9 D M A 7 x C *****#11Biometric Health Assessment A ahi Biometric health assessment 4-scans in less than 15-minutes for a biometric health report 01. Cardiovascular and mental health FaceScan uses facial blood flow analysis to deliver health vital estimates including blood pressure, heart rate, heart rate variability and breathing rate. This is promptly followed by the GAD7 and PHQ9, the clinical standard for anxiety and depression risk detection 02. Health at rest Health at rest focusses on the cardiovascular system and predicts resting heart rate risk. FingerScan employs Photoplethysmography (PPG) technology to detect volumetric changes in blood in peripheral circulation while at rest 03. Body dimension and composition BodyScan is built with proprietary computer vision and machine learning processing modules, which use over 1,000's of data points to generate and guide the scaled contour. This returns estimates on body dimension and composition, such as body fat %, waist hip ratio, and waist height ratio, comparable to gold standard methods 04. Post exertion recovery A 3-minute step test promptly followed by a FingerScan PPG to review cardiovascular fitness. This evenly paced stepping exercise reviews the associated risks with heart rate recovery and heart disease Investor Presentation - January 2024 This biometric health assessment contains estimations related to potential health risks. It is not intended to diagnose, treat, cure or prevent disease. Age 41 Height 166 cm Weight 58 kg Biological Sex Male Smoker Status Yes Blood Biomarkers Blood Lipid Estimated Risk Blood lipid risk refers to the likelihood of developing cardiovascular high levels of certain types of fats, or lipids, in the blood. The most c associated with CVD risk are cholesterol and triglycerides. Elevated Total Cholesterol Risk Total cholesterol is a measure of all your blood cholesterol compon risk for heart disease. Low Estimated Risk Getting the perfect FaceScan Position your face in the circle to start the stan Aim for 5-stars to achieve better results osition your finger over your back camera Scan in progress Avoid moving your finger What's included in the report? Estimations include: Cardiorespiratory fitness 10-year cardiovascular disease risk Framingham 10-year hard cardiovascular disease risk Resting heart rate Systolic blood pressure Diastolic blood pressure Blood sugar Body fat percentage Waist circumference Hip circumference Waist-to-hip ratio Waist-to-height ratio Move your face doser and position inside the outline Body mass index General anxiety Depression Arterial stiffness Visceral adiposity index О 2:00 Lipid accumulation product Blood lipids LDL cholesterol HDL cholesterol Triglycerides C-reactive protein inflammation 12#12Biometric health assessment Bloodless. Biometric. Ubiquitous. ● 61 outputs ● 41 biometrics • 5 health categories Health Risk Assessment About You Age 63 A ahi Weight 72 Height 168 cm Biologocial Sex Male Smoker Status No ■Cardiorespiratory Health Resting Heart Rate 75 bpm Cardiorespiratory Fitness Cardiorespiratory Fitness is the ability of the heart and lungs supporting working muscles during exercise. It is measured a maximum mount of oxygen a person can consume during exe Your Cardiorespiratory Fitness estimate is good. Blood Sugar Prolonged high blood glucose levels can increase the risk of heart disease, s kidney and vision problems. Blood Sugar Estimation An estimation of % HbA1c in your bloodstream is an indicator of your blood g Your blood sugar estimate is normal. You Metabolic Health Metabolic syndrome includes at least 3 of the following: High blood pressure . High blood sugar Excess body fat around the waist . Abnormal total cholesterol and high-density lipoprotein levels, which increases the risk of heart attack and stroke. Arterial Stiffness The elasticity of your arteries determine the circulation workload on your heart. Arterial stiffness increases with age, and increases the workload on the heart. Arterial stiffness is associated with increased blood pressure and insulin resistance. We estimate your Brachial- ankle pulse wave velocity (baPWV) as an indicator of arterial stiffness, used with your estimated lipid data to predict your risk for metabolic syndrome. 10-Year Cardiovascular Disease Risk Based on resting heart rate, BMI, age, gender, smoker status studies. You have an estimated 7% chance of developing Cardiovascular Disease in the next 10 years. Framingham 10-Year Hard Cardiovascular Disease Risk Calculated using the Framingham Coronary Heart Disease Ris You have an estimated 10% chance of having a heart attack in the next 10 years. ■Body Dimensions Waist Circumference: 83.5 cm Hip Circumference: 94.5 cm Waist to Hip Ratio: 0.88 Waist to Height Ratio: 0.5 Body Fat Percentage High percentage body fat increases your risk of obesity related diseases suc disease, high blood pressure, stroke and type-2 diabetes. Visceral Adiposity Index Excessive visceral fat results from a lack of exercise and excessive food intake. It is stored deep inside the belly, around your organs. The visceral adiposity index is an indicator of your cardio-metabolic risk based on your sex, body composition and blood lipids. You Lipid Accumulation Product The over-accumulation of lipids in your muscles and liver increases your risk of type 2 diabetes and heart disease. Blood Pressure ▲ You Blood Lipids You Self administered biometric health assessment from a user's own smartphone, no supporting equipment or health professional required Helping scale GPs' health-monitoring for larger populations Uncontrolled high blood pressure can increase the risk of hea kidney disease and vision loss. Body Mass Index Body Mass Index is a risk indicator for obesity related cardiovascular disease pressure, osteoarthritis, some cancers and diabetes. 118 mm Hg Your estimated central obesity risk is low. You Systolic Blood Pressure Indicates how much pressure your blood is exerting against y beats. Systolic Blood Pressure is a major risk factor for cardio over 50, and typically increases with age. Diastolic Blood Pressure 76 mm Hg Indicates how much pressure your blood is exerting against y is resting. Your blood pressure estimate is normal. Mental Health General Anxiety Increases risk of high blood pressure and heart disease. If you have heart dis disorders may increase the risk of coronary events. Your general anxiety estimate is low. Depression Increases risk of developing inflammation, diabetes, osteoporosis and heart Your depression estimate is low. Total Cholesterol: a measure of all your blood cholesterol components that indicate your risk of heart disease. ▲ You LDL Cholesterol: can build up on the walls of your arteries and increase your risk of heart disease. The lower your LDL-C concentration, the lower your risk. ▲ You HDL Cholesterol: protects against disease and prevents LDL buildup in the arteries. A higher HDL-cholesterol concentration may lower your risk of heart disease. You Triglycerides: high triglycerides increase the risk of stroke, heart attack, and heart disease. It is also a risk indicator for metabolic syndrome. Your blood lipid estimate is normal. ▲ You Investor Presentation - January 2024 Inflammation Inflammation is associated with stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes. C-reactive protein in your bloodstream is an indicator of inflammation. C-reactive protein estimate 0.42 mg/L Your inflammation estimate is normal.#13Biometric health assessment Triage into the right care pathways Promote early-risk detection and encourage sooner actions. Trigger a referral into higher-care, including telemedicine and telehealth based on a higher- risk indication from the biometric health assessment. Meanwhile lower-risk triggers can be referred into subclinical care options for general health maintenance. Investor Presentation - January 2024 Starting scan in... 3 10-minute biometric health assessment Cardiovascular Health Hypertension Moderate Risk Hypotension Normal Breathing Rate Elevated Mental Health Anxiety Index Moderate Your app name Your risk of hypertension is elevated We recommend contacting your local GP or medical professional for further testing. Depression Index Low Risk Now The results detect a potential elevated risk of hypertension and anxiety. All other vitals and risks reported as normal. Risk stratifications offer recommended care pathways. Your app name A telehealth consult is recommended to address the hypertension predicted risk. Try a 5-minute meditation break Elevated stress levels can heighten anxiety. Take a break and try a 5-minute meditation to calm those nerves. Now Your app name Try some aerobic exercise Aerobic exercise can help improve hypertension risks. Try going for a walk, having a jog or going for a swim. Meanwhile for lower risk or predicted health risks that can be monitored, you can connect to health programs or subclinical options. Now 14#14Our solutions Validation ESS Stellenbosch UNIVERSITY IYUNIVESITHI UNIVERSITEIT AHI is rapidly closing the gap to blood-based point-of-care testing. Early results from first pool of subjects comparing AHI's BHA accuracy to gold standard measurements. • 99.7% accuracy resting heart rate to 3-lead ECG • • ● • 95% accuracy Lipid Accumulation Product (LAP) to blood draw 90.5% accuracy waist-height ratio to biokineticist measure 85% accuracy Metabolic Syndrome (MetS) to blood draw 85% accuracy LDL Cholesterol to blood draw 83% accuracy Total Cholesterol to blood draw Investor Presentation - January 2024 *Note: incomplete and unpublished analysis, first data capture batch of n=21. 15#15Research-led, science backed and published globally The research and studies associated with the efficacy of our technologies has been featured in luminary publications. JOURNAL OF COMMUNITY MEDICINE & PUBLIC HEALTH CARE The Hidden Public Health Problem of Inadequate Sleep: Deploying Digital Mobile Technology to Improve Employee Sleep Hygiene in Asia Obesity Research & Clinical Practice Agreement of anthropometric and body composition measures predicted from 2D smartphone images and body impedance scales with criterion methods American Heart Association. High Impact Employee Stress Reduction and Wellness Promotion Delivered via Digital Mobile Technology in the Construction and Aviation Industries SCIENTIFIC REPORTS Obesity Research & Clinical Practice Obesity Facts The European Journal of Obesity JOURNAL OF MOGY JDD British Journal of Nutrition NS OCRTY DXA reference values and anthropometric screening for visceral obesity in Western Australian adults. Obesity and visceral fat in Indonesia; An unseen epidemic? A study using iDXA and surrogate anthropometric measures. Smartphone derived body composition and anthropometry for tracking weight loss Artificial Intelligence in the Evaluation of Telemedicine Dermatology Patients Longitudinal concordance of body composition and anthropometric assessment by a novel smartphone application across a 12-week self-managed weight loss intervention frontiers in Public Health Journal of Ecophysiology and Occupational Health No retrenchment from employee empowerment Employer wellness imperatives and opportunities emerging from the COVID-19 pandemic. Employee Wellness in a Changing Climate: Environmental Heat Stress Driving Need for Targeted Health Promotion and Risk Reduction Health Promotion Journal of Australia Contextual wellness in the age of COVID-19: Managing disproportionate pandemic anxiety and stress in Australia, Singapore and other nations achieving disease control success. IEEE Transactions on Medical Imaging Superiority of Artificial Intelligence in the Diagnostic Performance of Malignant Melanoma Compared to Dermatologists and Primary Care Providers Investor Presentation - January 2024 16#16New solutions Atrial Fibrillation SaMD to launch Q2-2024 AHI plans to release Software-as-a-Medical-Device (SaMD) Atrial Fibrillation scan as part of its Biometric health assessment (BHA) from Q2-2024, as well as the Atrial Fibrillation scan a stand- alone service. FDA SFDA الهيئة العامة للغذاء والدواء Saudi Food & Drug Authority Administration TGA CERTIFIED Therapeutic Goods of Australia Investor Presentation - January 2024 The PPG fingerscan is a function of phase 2 and phase 4 of AHI's BHA and will soon offer medically approved atrial-fibrillation detection. CE The technology has medical approval in Australia, USA, Singapore, EU, UK, UAE and Saudi Arabia for near clinical. The global prevalence of atrial fibrillation (AF) is approximately 60 million cases, of which up to 40% AF patients are asymptomatic. Source: https://wcsecure.weblink.com.au/clients/advancedhumanimaging/v2/headline.aspx?headlineid=61184064 17#17HIPAA • ССРА Privacy and security Global, private and secure. We collaborate with our partners to establish a shared responsibility model, to ensure our digital health solutions comply with applicable regulations in those territories including HIPAA*, GDPR and more. This model ensures that sensitive health information is effectively protected at all touch points. Furthermore, Data Processing Agreements outlining the requirements and obligations we undertake are entered into with partners to ensure global privacy standards are met and maintained. Our technology meets OWASP standards and is consistently reviewed by independent security experts. Investor Presentation - January 2024 LGPD 00000 GDPR > POPIA APA 8 No images or videos leave the device Only encrypted data-signals are 8 sent to the cloud for processing and analysis 8 Users choose who to share results with and when * HIPAA compliance applies to FaceScan and BodyScan data processing. 18#18Simple and scalable for global populations AHI Biometric Scans SDK Integration T Scan started. Remain still and keep breathing as normal Position Your Finger Over the Back Camera Scan in Progress. Avoid moving your finger. O 2:00 Investor Presentation - January 2024 1 Partner app I Scalable Care More Health Screenings Earlier risk Detection Health Literacy Earlier Intervention 19#19Integrated Care Solution Using AHI's Integrated Enterprise Software Platform Software Solutions Engagement layer Single digital interface for Payor and Patient. Digital Risk Screening e-Scripting Medicine Risk Management Software Solutions Technology-based on international standards of interoperability with health databases and EHR. Telehealth Services Script Fulfillment Software Data and analytics Rich patient database to drive burden of disease progression and health predictions. Reporting Payors population based on epidemiological predictive surveillance, risk dashboards and spend patterns. Investor Presentation - January 2024 Reporting PBM Pathology Single digital interface во Enterprise Integrated Software Platform for patients Epidemiological Predictive Surveillance Risk Dashboards and payors Biomarkers 14 Fraud, waste and abuse management Spend Patterns Phenotyping Profiles Data & analytics Blood Proxies Predictive Models AI/ML engines 20 20#20Our positioning A + Customer segments & ROI Clinical trials & RWE $53B industry 5% CAGR Priced from $1 - $29 Health & Life Insurance $5T industry, 3% CAGR² Payor ROI - why customers buy dHaaS: 1. Reduced cost and risk (through early detection and intervention opportunities) 2. Improved health and care outcomes 3. Process automation (HR, health care providers) 4. Data - better understand customer needs, improving sales of core goods/services better Government Dept's & Ministry of Health $16T industry 9% CAGR4,5 Healthcare providers $11T industry 9% CAGR³ Investor Presentation - January 2024 Sources 1. https://www.globenewswire.com/en/news- release/2022/04/11/2420173/0/en/Worldwide-3-Trillion-Health-Insurance-Market-Size-is- Expected-to-Grow-at-a-CAGR-of-over-4-4-During-2022-2028-Vantage-Market- Research.html 2. https://www.mordorintelligence.com/industry-reports/global-life-and-non-life-insurance- market--growth-trends-and-forecast-2020---2025 3. https://www.businesswire.com/news/home/20190625005862/en/The-11.9-Trillion- Global-Healthcare-Market-Key-Opportunities-Strategies-2014-2022--- ResearchAndMarkets.com 4. https://stats.oecd.org/Index.aspx?DataSetCode=SHA 5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695957/ 21#21Engaged customers AHI has the below current partners who represent a total addressable audience of over 250 million people. AHI is working with each of these partners to complete technical integration and launch to these audiences in Q1 and Q2-2024. Every engaged user attracts AHI license fees. Our network of partners and customers represent 250 million potential users DONE TRUCONNECT BEARN earn while you burn! CLINIC biomorphik Nexus Vita A ACTIVATE HEALTH CHECK >*PHARMAK IntelliGen Investor Presentation - January 2024 @ The ARC Body Vitals Meals bizbaz INTELLIGENT FINANCE MVMNT CHANGLIN NETWORK TECHNOLOGY A upvio Unisure® health life global SCOR#22Business Targets in H1-2024 LAUNCH AT LEAST 4 COMMERCIAL PARTNERS Bearn - USA OneClinic Vietnam Pharmak - UAE Upvio USA, Asia CLOSE AT LEAST 2 MAJOR PIPELINE PROSPECTS China Vietnam South East Asia Middle East SaMD CERTIFICATION Clinical or near-clinical use AHI are in discussions with strategic partners and investors, we welcome your conversation. Investor Presentation - January 2024 23#23Thank-you Scott Montgomery Chief Executive Officer [email protected] For more information on how Advanced Health Intelligence how our technologies can help you, find out more at https://ahi.tech Dahi Corporate Headquarters Suite 5, 71-73 South Perth Esplanade, South Perth WA 6151 [email protected] Vlado Bosanac Founder/Head of Strategy [email protected] Other locations / Asia Pacific: Perth, Melbourne, Sydney, Singapore North America: Vancouver, Denver South Africa: Cape Town Europe: Amsterdam © 2023 Advanced Health Intelligence Ltd. All rights reserved. Apple, iPad, iPhone and App store logos are trademarks of Apple Inc. registered in the U.S. and other countries. Android and Google play are trademarks of Google LLC. All other trademarks are property of their respective owners. SPR_MTG_AHI230203